Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 14/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15076729 | 0.92 | CYP3A4 (0.65) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL15076751 | 0.91 | CYP3A4 (0.73) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL15076761 | 0.89 | CYP3A4 (0.64) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL15076393 | 0.87 | CYP3A4 (0.57) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL15076558 | 0.86 | CYP3A4 (0.66) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL15076808 | 0.84 | CYP3A4 (0.73) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL15076399 | 0.84 | CYP3A4 (0.72) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL15076724 | 0.84 | CYP3A4 (0.82) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL15076423 | 0.82 | LMNA (0.53) | CYP3A4CYP2D6CYP2C9CYP2C19KCNH2 | |
| SCHEMBL15076730 | 0.82 | MAPT (0.55) | ENPP2LPAR1TP53MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312160-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-10196376-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-3312160-A1 | HEPATITIS B ANTIVIRAL AGENTS | Novira Therapeutics Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC | 2017-11-23 | — | — | US | disclosed |
| US-9751857-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751857-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2794565-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9676747-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676747-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9061008-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150152073-A1 | Hepatitis B Antiviral Agents | NOVIRA THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20150152073-A1 | Hepatitis B Antiviral Agents | NOVIRA THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. | 2014-06-26 | — | — | US | disclosed |
| US-8629274-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629274-B2 | Hepatitis B antiviral agents | NOVIRA THERAPEUTICS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152073-A1 | Hepatitis B Antiviral Agents | HAVCR2, EIF2AK2, IRF3 | CYP3A4 1962/4885CYP2D6 2915/4885CYP2C9 3466/4885 |
| US-20140178337-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | CYP3A4 1962/4885CYP2D6 2915/4885CYP2C9 3466/4885 |
| US-10196376-B2 | Hepatitis B antiviral agents | HAVCR2, EIF2AK2, IRF3 | CYP3A4 1962/4885CYP2D6 2915/4885CYP2C9 3466/4885 |
| US-20170334882-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | CYP3A4 1962/4885CYP2D6 2915/4885CYP2C9 3466/4885 |
| US-20130251673-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, EIF2AK2, IRF3 | CYP3A4 1962/4885CYP2D6 2915/4885CYP2C9 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.